Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 ≤90 U/mL and Comparison to the CONKO-001 Trial

This analysis demonstrates that patients with postresection CA 19-9 values ≥90 U/mL had a significantly worse survival. Patients with pancreatic head tumors treated with Gem with CA 19-9 serum level of <90 U/mL and per protocol RT had favorable survival compared to that seen in the CONKO trial. CA 19-9 is a stratification factor for the current RTOG adjuvant pancreas trial (0848).